Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 6,612 shares of the business’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $18.11, for a total value of $119,743.32. Following the completion of the sale, the director owned 365,273 shares of the company’s stock, valued at $6,615,094.03. The trade was a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Maplight Therapeutics Trading Down 4.8%

NASDAQ MPLT traded down $0.89 on Friday, reaching $17.69. 259,632 shares of the company’s stock traded hands, compared to its average volume of 186,272. The firm has a market cap of $802.60 million and a PE ratio of -0.48. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $21.55. The stock has a 50-day moving average price of $17.62.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Analyst Ratings Changes

Several research analysts have recently commented on the company. Leerink Partners started coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price objective on the stock. Weiss Ratings began coverage on Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Morgan Stanley initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target on the stock. Jefferies Financial Group began coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $32.00 price objective for the company. Finally, Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.